AU2003264037B2 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms - Google Patents
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms Download PDFInfo
- Publication number
- AU2003264037B2 AU2003264037B2 AU2003264037A AU2003264037A AU2003264037B2 AU 2003264037 B2 AU2003264037 B2 AU 2003264037B2 AU 2003264037 A AU2003264037 A AU 2003264037A AU 2003264037 A AU2003264037 A AU 2003264037A AU 2003264037 B2 AU2003264037 B2 AU 2003264037B2
- Authority
- AU
- Australia
- Prior art keywords
- cell
- cells
- nicotinamide
- sir2
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010219395A AU2010219395B2 (en) | 2002-08-09 | 2010-09-10 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40225402P | 2002-08-09 | 2002-08-09 | |
| US60/402,254 | 2002-08-09 | ||
| US42861402P | 2002-11-22 | 2002-11-22 | |
| US60/428,614 | 2002-11-22 | ||
| PCT/US2003/025016 WO2004016726A2 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010219395A Division AU2010219395B2 (en) | 2002-08-09 | 2010-09-10 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003264037A1 AU2003264037A1 (en) | 2004-03-03 |
| AU2003264037B2 true AU2003264037B2 (en) | 2010-06-17 |
Family
ID=31720582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003264037A Ceased AU2003264037B2 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| AU2010219395A Ceased AU2010219395B2 (en) | 2002-08-09 | 2010-09-10 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010219395A Ceased AU2010219395B2 (en) | 2002-08-09 | 2010-09-10 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP1551964A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2005535342A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2003264037B2 (cg-RX-API-DMAC10.html) |
| CA (2) | CA2421269A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2004016726A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| US20050096256A1 (en) | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| WO2006072809A2 (en) * | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| SI1794306T1 (sl) | 2004-09-24 | 2010-04-30 | Bayer Bioscience Nv | Rastline, odporne na stres |
| US20090012130A1 (en) * | 2005-01-25 | 2009-01-08 | The Johns Hopkins University | Strategies for Designing Drugs that Target the Sir2 Family of Enzymes |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| ES2331022T3 (es) * | 2005-06-15 | 2009-12-18 | Bayer Bioscience N.V. | Metodos para aumentar la resistencia de las plantas a condiciones hipoxicas. |
| KR20090007718A (ko) * | 2006-03-21 | 2009-01-20 | 바이엘 바이오사이언스 엔.브이. | 스트레스 저항성 식물 |
| ES2513143T3 (es) | 2006-12-11 | 2014-10-24 | Japan Science And Technology Agency | Regulador del crecimiento vegetal y sus usos |
| ES2647918T3 (es) * | 2007-11-13 | 2017-12-27 | Japan Science And Technology Agency | Composición para la producción de cuerpos de plantas que tengan un contenido de azúcar mejorado y uso de la misma |
| JP5570731B2 (ja) * | 2008-02-28 | 2014-08-13 | 旭化成ファーマ株式会社 | ピロリン酸の測定方法 |
| WO2009108999A1 (en) | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
| JP2011115098A (ja) * | 2009-12-04 | 2011-06-16 | Nippon Menaade Keshohin Kk | 加齢による皮膚明度の低下を予測する皮膚評価方法 |
| KR101703180B1 (ko) | 2011-12-12 | 2017-02-06 | 오카야마켄 | 식물의 아미노산 함량을 높이기 위한 화합물 및 그 이용 |
| WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| WO2015069860A1 (en) * | 2013-11-06 | 2015-05-14 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| JP6623015B2 (ja) * | 2014-09-29 | 2019-12-18 | 国立研究開発法人理化学研究所 | 植物の耐塩性向上剤 |
| WO2020097116A1 (en) * | 2018-11-05 | 2020-05-14 | Rejuvenation Therapeutics | Compositions and methods for culturing yeast cells |
| US20220324899A1 (en) * | 2019-08-14 | 2022-10-13 | Metro International Biotech, Llc | Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide |
| CN111394268B (zh) * | 2019-12-20 | 2021-06-18 | 合肥康诺生物制药有限公司 | 基因工程菌及其构建方法、应用,生产nad+的方法 |
| CN112451673A (zh) * | 2020-12-10 | 2021-03-09 | 汤臣倍健股份有限公司 | 线粒体功能干预材料在制备改善线粒体功能的保健品或药品中的应用及其筛选方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| HK1008049A1 (en) | 1987-09-11 | 1999-04-30 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and use therefor |
| ATE110108T1 (de) | 1987-12-11 | 1994-09-15 | Whitehead Biomedical Inst | Genetische modifizierung von endothelialen zellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| WO1994006920A1 (en) | 1992-09-22 | 1994-03-31 | Medical Research Council | Recombinant viruses displaying a nonviral polypeptide on their external surface |
| CA2148934C (en) | 1992-11-09 | 2005-08-02 | French W. Anderson | Targetable vector particles |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| CA2203809C (en) | 1994-10-28 | 2008-06-03 | James M. Wilson | Recombinant adenovirus and methods of use thereof |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| CA2206683A1 (en) | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
| DE69636863T2 (de) | 1995-02-24 | 2007-11-15 | Trustees Of The University Of Pennsylvania | Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
| GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| CN1478149A (zh) * | 2000-10-03 | 2004-02-25 | 宝生物工程株式会社 | 生理活性物质的筛选方法 |
| US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| SI1794306T1 (sl) * | 2004-09-24 | 2010-04-30 | Bayer Bioscience Nv | Rastline, odporne na stres |
| US9515947B1 (en) | 2013-03-15 | 2016-12-06 | EMC IP Holding Company LLC | Method and system for providing a virtual network-aware storage array |
| KR20160071054A (ko) | 2014-12-11 | 2016-06-21 | 에스케이하이닉스 주식회사 | 반도체 메모리 장치 및 그의 동작 방법 |
| US9609948B2 (en) | 2015-04-28 | 2017-04-04 | Qianglong Furniture Co., Ltd. | Rotating armrest apparatus |
-
2003
- 2003-03-07 CA CA002421269A patent/CA2421269A1/en not_active Abandoned
- 2003-08-08 AU AU2003264037A patent/AU2003264037B2/en not_active Ceased
- 2003-08-08 CA CA002495185A patent/CA2495185A1/en not_active Abandoned
- 2003-08-08 JP JP2004529297A patent/JP2005535342A/ja active Pending
- 2003-08-08 EP EP03788377A patent/EP1551964A4/en not_active Withdrawn
- 2003-08-08 EP EP11179088A patent/EP2431480A3/en not_active Withdrawn
- 2003-08-08 WO PCT/US2003/025016 patent/WO2004016726A2/en not_active Ceased
-
2010
- 2010-07-20 JP JP2010162637A patent/JP2011015682A/ja active Pending
- 2010-09-10 AU AU2010219395A patent/AU2010219395B2/en not_active Ceased
-
2015
- 2015-06-10 JP JP2015117465A patent/JP6602561B2/ja not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| ANDERSON ET AL, J. Biol. Chem. March 2002, Vol 277, No. 21, pages 18881-18890 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1551964A2 (en) | 2005-07-13 |
| AU2003264037A1 (en) | 2004-03-03 |
| WO2004016726A9 (en) | 2005-08-04 |
| CA2421269A1 (en) | 2004-02-09 |
| AU2010219395B2 (en) | 2011-07-14 |
| WO2004016726A2 (en) | 2004-02-26 |
| EP1551964A4 (en) | 2010-07-28 |
| AU2010219395A1 (en) | 2010-09-30 |
| EP2431480A3 (en) | 2012-09-05 |
| CA2495185A1 (en) | 2004-02-26 |
| JP2005535342A (ja) | 2005-11-24 |
| JP2015198665A (ja) | 2015-11-12 |
| EP2431480A2 (en) | 2012-03-21 |
| WO2004016726A3 (en) | 2005-05-19 |
| JP6602561B2 (ja) | 2019-11-06 |
| JP2011015682A (ja) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010219395B2 (en) | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | |
| EP1851240B1 (en) | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | |
| Vlach et al. | Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 | |
| AU699969B2 (en) | Isolated p27 protein and its encoding nucleic acid molecules | |
| Satyanarayana et al. | Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms | |
| Moss et al. | Identification of the cAMP-dependent protein kinase and protein kinase C phosphorylation sites within the major intracellular domains of the beta 1, gamma 2S, and gamma 2L subunits of the gamma-aminobutyric acid type A receptor. | |
| Chen et al. | Identification of Nck family genes, chromosomal localization, expression, and signaling specificity | |
| Graeser et al. | Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells | |
| Hu et al. | 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling | |
| Yamaguchi et al. | Calbrain, a novel two EF-hand calcium-binding protein that suppresses Ca2+/calmodulin-dependent protein kinase II activity in the brain | |
| US6635450B1 (en) | Isolated P27 protein, nucleic acid molecules encoding same, methods of identifying agents acting on same, and uses of said agents | |
| Dimopoulos | A Role for Glycogen Synthase Kinase 3 beta in the Regulation of Glucagon Gene Transcription by Insulin | |
| US20020110886A1 (en) | Isolated p27 protein and methods for its production and use | |
| Ibarra-Sánchez | Biochemical and cellular function of t-cell protein tyrosine phosphatase | |
| Xu | Identification of Wnt/GSK3 Regulated Proteolysis Targets in Addition to [B]-catenin | |
| Kim et al. | Dynein Light Chain LC8 Inhibits Osteoclast | |
| Carlson | Activation of Gcn2 by Pharmacological Agents Designed to be Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTOR BITTERMAN, KEVIN J.. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTOR BITTERMAN, KEVIN J. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |